Table 2. Concordance between conventional and UDS methods in clinical sample testing.
| Baseline | Post AC220 | |||||
|---|---|---|---|---|---|---|
| UPN | Age | Cytogenetic Profile | BMB (%) | FLT3 ITD (%) | BMB (%) | FLT3 ITD (%) |
| 6 | 63 | 46XY | 100 |
ITD 1863 (33bp):0,7% ITD 1906 (36bp):77% |
100 | ITD 1906(36bp):96% |
| 7 | 71 | 46XY | 100 | ITD 1920 (90bp):29% | 5 | ITD 1920 (90bp):5% |
| 8 | 40 | 46XX | 80 | ITD 1922(69 bp): 1,8% | 100 | ND |
| 9 | 55 | 46XX;t(2;8)(q15,q24) | 100 | ITD 1874 (45bp):39,8% | 100 | ITD 1874 (45bp):54,4% |
| 10 | 60 | 46XY | 80 | ND | 90 | ND |
| 11 | 63 | Complex | 100 | ND | 100 | ND |
| 12 | 70 | 47XY;+11 | 90 | ITD 1909 (45bp):27,3% | 80 | ITD 1909 (45bp):20,7% |
| 13 | 50 | 46XX;t(6,11)(q27,q23) | 100 | ND | 100 | ND |
| 14 | 55 | 47XX;+21 | 100 | ND | 100 | ND |
| 15 | 67 | 46XX | 80 | ND | 80 | ND |
Clinical AML samples from patients treated with the FLT3 inhibitor AC220 were screened for the presence of ITD mutations before and after therapy by PCR, followed by DHPLC and Sanger Sequencing, and by UDS (BMB: bone marrow blasts, ND: not detected). The ITD mutations in red were detected exclusively by UDS analysis.